<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04329806</url>
  </required_header>
  <id_info>
    <org_study_id>190479</org_study_id>
    <secondary_id>R01HL149386</secondary_id>
    <nct_id>NCT04329806</nct_id>
  </id_info>
  <brief_title>Sympathetic Mechanisms in the Cardiovascular and Metabolic Alterations of Obesity</brief_title>
  <official_title>Sympathetic Mechanisms in the Cardiovascular and Metabolic Alterations of Obesity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Italo Biaggioni</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to study the role of sympathetic mechanisms involved in chronic&#xD;
      regulation of cardiovascular and metabolic abnormalities seen in obesity. The investigators&#xD;
      will study the effects chronic sympathetic inhibition on insulin sensitivity, inflammation&#xD;
      and endothelial function in obese hypertensive human subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Continuing Review (CR, 2021/08/04) Update: Removal of the angiotensin receptor blockade arm&#xD;
      of the study&#xD;
&#xD;
      The presence of obesity increases the risk for hypertension and diabetes, in part due to the&#xD;
      development of insulin resistance. Obesity is also associated with sympathetic activation and&#xD;
      the overarching hypothesis is that sympathetic activation contributes to insulin resistance&#xD;
      with impairment of its vascular and metabolic actions. Preliminary studies suggest that 1)&#xD;
      Blood pressure can be normalized by autonomic blockade in obese hypertensives, 2) Sympathetic&#xD;
      activation provides no metabolic benefit because the increase in resting energy expenditure&#xD;
      associated with obesity is due to an increase in fat free mass rather than sympathetic&#xD;
      activation. On the contrary, autonomic blockade: 3) Improves insulin sensitivity in obese&#xD;
      hypertensives, 4) Reverses their impaired NO-mediated dilation, and 5) Reduces plasma&#xD;
      isoprostanes, a measure of oxidative stress. Furthermore, these abnormalities are&#xD;
      interrelated in negative feedback loops, whereby inflammation/oxidative stress impairs nitric&#xD;
      oxide mechanisms, which in turn reduces insulin-mediated vasodilation important for substrate&#xD;
      delivery, thus contributing to insulin resistance; insulin resistance leads to compensatory&#xD;
      increases in insulin levels, which contributes to further sympathetic activation. Current&#xD;
      treatment guidelines do not specifically address the treatment of obesity hypertension, and&#xD;
      do not target sympathetic activation as a first line approach. It is important, therefore, to&#xD;
      determine whether or not targeting sympathetic activation offers unique advantages in the&#xD;
      treatment of obesity hypertension over current approaches. The investigators propose a&#xD;
      proof-of-concept mechanistic study comparing the metabolic, vascular, and anti-inflammatory&#xD;
      effects of sympathetic inhibition, calcium channel blockade and angiotensin receptor blockade&#xD;
      in obesity hypertension. The investigators will test the hypotheses that sympathetic&#xD;
      activation contributes to 1) metabolic insulin resistance, which impairs the suppression of&#xD;
      endogenous glucose production and the stimulation of glucose uptake normally provided by&#xD;
      insulin, 2) vascular insulin resistance, which impairs insulin-mediated vasodilation and&#xD;
      microvascular recruitment that normally promote glucose uptake, and 3) inflammation and&#xD;
      oxidative stress, which contribute to insulin resistance and hypertension. The proposed&#xD;
      studies will gauge the contribution of sympathetic activation to the cardiovascular and&#xD;
      metabolic complications of obesity and provide the mechanistic insight to determine whether&#xD;
      or not it should foster the efforts currently under way to develop novel therapies targeting&#xD;
      sympathetic activation for hypertension.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 23, 2021</start_date>
  <completion_date type="Anticipated">April 2025</completion_date>
  <primary_completion_date type="Anticipated">April 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin Sensitivity</measure>
    <time_frame>6 hours</time_frame>
    <description>Dose response curve to insulin ( measure as glucose infusion rate In mg/kg/min)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Obesity-Associated Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>Moxonidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Moxonidine to be administered at a dose to produce a decrease in BP of at least 20% of baseline for 9 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amlodipine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Amlodipine to be administered at a dose to produce a decrease in BP of at least 20% of baseline for 9 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxonidine 0.2 MG</intervention_name>
    <description>Moxonidine 0.2 MG twice daily</description>
    <arm_group_label>Moxonidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine 5 MG</intervention_name>
    <description>Amlodipine 5 MG twice daily</description>
    <arm_group_label>Amlodipine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males and females of all races between 18 and 60 years of age&#xD;
&#xD;
          -  Hypertension defined by two or more properly measured seated blood pressure readings&#xD;
             &gt;130/85 mmHg or currently on antihypertensive medication.&#xD;
&#xD;
          -  Obesity will be defined as having a body mass index (BMI) â‰¥ 30 kg/m2.&#xD;
&#xD;
          -  Able and willing to provide informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or breast feeding&#xD;
&#xD;
          -  Current smokers or history of heavy smoking (&gt;2 packs/day)&#xD;
&#xD;
          -  History of alcohol or drug abuse&#xD;
&#xD;
          -  Previous allergic reaction to study medications&#xD;
&#xD;
          -  Evidence of type I diabetes&#xD;
&#xD;
          -  Cardiovascular disease other than hypertension&#xD;
&#xD;
          -  History of serious cerebrovascular disease&#xD;
&#xD;
          -  History or presence of immunological or hematological disorders&#xD;
&#xD;
          -  Impaired renal function&#xD;
&#xD;
          -  Treatment with any investigational drug in the 1 month preceding the study&#xD;
&#xD;
          -  Inability to give, or withdraw, informed consent&#xD;
&#xD;
          -  Other factors which in the investigator's opinion would prevent the subject from&#xD;
             completing the protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Italo Biaggioni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cynthia D Laws, MS,RHIA,CCRP</last_name>
    <phone>615-421-1994</phone>
    <email>autonomicgroup@vumc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alfredo Gamboa</last_name>
    <phone>615-875-1003</phone>
    <email>alfredo.gamboa@vumc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cynthia D Laws, MS, RHIA,ASQ-CQIA, CCRP</last_name>
      <phone>615-421-1994</phone>
      <email>autonomicgroup@vumc.org</email>
    </contact>
    <contact_backup>
      <last_name>Emily C Smith, RN</last_name>
      <phone>615.875.1516</phone>
      <email>autonomics@vumc.org</email>
    </contact_backup>
    <investigator>
      <last_name>Italo Biaggioni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alfredo Gamboa, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luis E Okamoto, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cyndya A Shibao, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andre Diedrich, MD/PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emily C Smith</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 16, 2020</study_first_submitted>
  <study_first_submitted_qc>March 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2020</study_first_posted>
  <last_update_submitted>August 12, 2021</last_update_submitted>
  <last_update_submitted_qc>August 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Italo Biaggioni</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Moxonidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

